Next Article in Journal
Immunogenicity and Efficacy of Zika Virus Envelope Domain III in DNA, Protein, and ChAdOx1 Adenoviral-Vectored Vaccines
Previous Article in Journal
Correction: miR29a and miR378b Influence CpG-Stimulated Dendritic Cells and Regulate cGAS/STING Pathway
Open AccessArticle

E. coli-Produced Monophosphoryl Lipid a Significantly Enhances Protective Immunity of Pandemic H1N1 Vaccine

1
Infectious Disease Research Center, Korea Research Institute of Bioscience and Biotechnology (KRIBB), Daejeon 34141, Korea
2
Department of Biosystems and Bioengineering, KRIBB School of Biotechnology, University of Science and Technology, Daejeon 34113, Korea
3
College of Veterinary Medicine, Chungnam National University, Daejeon 34134, Korea
4
Eubiologics. Co., Ltd., V Plant, Gangwon-do 24410, Korea
*
Author to whom correspondence should be addressed.
Vaccines 2020, 8(2), 306; https://doi.org/10.3390/vaccines8020306
Received: 8 May 2020 / Revised: 4 June 2020 / Accepted: 11 June 2020 / Published: 16 June 2020
(This article belongs to the Section Influenza Virus Vaccines)
Emerging influenza viruses pose an extreme global risk to human health, resulting in an urgent need for effective vaccination against influenza infection. Adjuvants are vital components that can improve vaccine efficacy, yet only a few adjuvants have been licensed in human vaccines. Here, we investigate the adjuvant effects of Escherichia coli-produced monophosphoryl lipid A (MPL), named EcML, in enhancing the immunogenicity and efficacy of an influenza vaccine. Similar to MPL, EcML activated dendritic cells and enhanced the antigen processing of cells in vitro. Using ovalbumin (OVA) as a model antigen, EcML increased OVA-specific antibody production, cytotoxic T lymphocyte activity. The safety of EcML was demonstrated as being similar to that of MPL by showing not significant in vitro cell cytotoxicity but transient systemic inflammatory responses within 24 h in OVA immunized mice. Importantly, mice vaccinated with pandemic H1N1 (pH1N1) vaccine antigen, combined with EcML, were fully protected from pH1N1 virus infection by enhanced influenza-specific antibody titers, hemagglutination inhibition titers, and IFN-γ- secreting cells. Taken together, our results strongly suggest that EcML might be a promising vaccine adjuvant for preventing influenza virus infection. View Full-Text
Keywords: adjuvant; vaccine efficacy; influenza virus; monophosphoryl lipid A; antibody production; cytotoxic T lymphocyte adjuvant; vaccine efficacy; influenza virus; monophosphoryl lipid A; antibody production; cytotoxic T lymphocyte
Show Figures

Figure 1

MDPI and ACS Style

Nguyen, Q.T.; Kim, E.; Yang, J.; Lee, C.; Ha, D.H.; Lee, C.G.; Lee, Y.R.; Poo, H. E. coli-Produced Monophosphoryl Lipid a Significantly Enhances Protective Immunity of Pandemic H1N1 Vaccine. Vaccines 2020, 8, 306.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Search more from Scilit
 
Search
Back to TopTop